Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Analysts at HC Wainwright

Equities research analysts at HC Wainwright started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research note issued on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS and Q4 2027 earnings at $4.16 EPS.

Other equities research analysts have also recently issued reports about the stock. Citigroup increased their price objective on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday. UBS Group restated a “buy” rating and issued a $735.00 target price on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Barclays cut their price target on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Finally, Wells Fargo & Company began coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Price Performance

Madrigal Pharmaceuticals stock opened at $400.43 on Wednesday. The stock’s 50 day moving average is $492.40 and its 200 day moving average is $498.45. Madrigal Pharmaceuticals has a one year low of $353.54 and a one year high of $615.00. The firm has a market cap of $9.25 billion, a P/E ratio of -66.96 and a beta of -0.98. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.93%. The business had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. During the same quarter in the prior year, the firm posted ($5.08) EPS. As a group, research analysts expect that Madrigal Pharmaceuticals will post -7.03 EPS for the current year.

Insider Activity at Madrigal Pharmaceuticals

In related news, General Counsel Shannon T. Kelley sold 664 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the transaction, the general counsel directly owned 11,474 shares of the company’s stock, valued at $5,908,765.78. This represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 5,221 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the transaction, the chief executive officer directly owned 197,746 shares in the company, valued at approximately $107,255,452.94. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 12,247 shares of company stock valued at $6,581,182. Insiders own 17.60% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. J. Goldman & Co LP acquired a new position in shares of Madrigal Pharmaceuticals during the second quarter valued at about $2,722,000. Royal Bank of Canada grew its stake in shares of Madrigal Pharmaceuticals by 22.5% in the 1st quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company’s stock valued at $6,557,000 after buying an additional 2,303 shares during the period. Hsbc Holdings PLC grew its stake in shares of Madrigal Pharmaceuticals by 1,738.3% in the 2nd quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company’s stock valued at $10,868,000 after buying an additional 19,139 shares during the period. Sivik Global Healthcare LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $1,260,000. Finally, Legal & General Group Plc acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $6,630,000. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results substantially beat expectations. Madrigal reported earnings of $1.83 per share, versus the consensus estimate of a $1.09 loss, and revenue of $431.3 million, ahead of the $404.2 million estimate. Rezdiffra sales growth helped drive the results, with coverage reporting sales surpassed $1 billion. Madrigal Q3 results
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. Canaccord lifted its target to $633 from $612, Truist to $743 from $709, and Citi to $760 from $725. The upgrades reflect substantial potential upside, though targets are analysts’ estimates, not guarantees. Canaccord rating Truist rating Citi rating
• Neutral Sentiment: Clinical development continues, but key data are not imminent. Madrigal expects the MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a 2,000-plus-patient MAESTRO-CSPH study. These programs offer longer-term potential, but their timelines mean they are less likely to provide a near-term catalyst. Madrigal clinical plans
• Negative Sentiment: Legal investigations and profit-sustainability questions remain risks. Two law firms announced investigations into potential securities-law violations; these are allegations under investigation, not findings of wrongdoing. Separate coverage cited investor concerns about near-term profitability, which could temper the reaction to the strong quarterly beat. Kirby McInerney investigation notice Kaplan Fox investigation notice

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.